You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company notified the Securities and Exchange Commission of the subpoena and noted that it will delay filing its annual earnings for 2015.
Abbott's move came as somewhat of a surprise, but analysts have noted the potential for a trend in point-of-care diagnostics acquisitions.
Alere will become an Abbott subsidiary, and Alere shareholders will receive $56 per common share in cash at the completion of the transaction.
The company reported $1.22 billion in Q4 Worldwide Diagnostics sales, including $126 million in molecular diagnostics sales due to growth in infectious disease testing.
Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The virus, known as HPgV-2, was detected in blood samples from individuals with concurrent hepatitis C virus infections.
The amendment changes product fees Abbott pays to BG Medicine for galectin-3 test sales in exchange for making two payments totaling $1 million.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.